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This multicenter phase II study evaluated, in chemonaive patients with stage IIIB–IV NSCLC, age X70 and with a performance status
0–2, the activity, efficacy and tolerability of planned sequential administration of gemcitabine 1200mgm
 2 on days 1 and 8 every 3
weeks for three courses followed by three cycles of docetaxel 37.5mgm
 2 on days 1 and 8 every 3 weeks, provided there was no
evidence of disease progression. A total of 56 patients entered the study. According to intention-to-treat analysis, the objective
response rate was 16.0% (95% CI 7.6–28.3%); 23 patients (41.0%) had stable disease and 24 patients (43%) had progressive disease.
Five patients who had a stable disease after three courses of gemcitabine obtained a conversion to partial response by docetaxel.
Median time to progression was 4.8 months (95% CI 3.6–6.0 months) and median duration of survival was 8.0 months (95% CI
5.6–10.5 months). The 1-year survival rate was 34%. No grade 4 haematological toxicity was observed and grade 3 neutropenia and
thrombocytopenia were reported in 5.4 and 3.6% of the patients, respectively. Grade 3/4 mucositis and grade 3 diarrhoea, both
occurred in 3.6% of the patients and grade 3 asthenia was observed in 9% of patients. One patient reported a grade 4 skin toxicity.
No treatment-related deaths occurred. Sequential gemcitabine and docetaxel is a well-tolerated and effective regimen in elderly
advanced NSCLC patients.
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Lung cancer is the leading cause of cancer-related deaths in
Western countries. Non-small-cell lung cancer, (NSCLC) accounts
for 87% of primary lung cancers and approximately two-thirds of
NSCLC patients are in an advanced stage at diagnosis (Govindan
et al, 2006). Most malignancies, including lung cancer, occur more
commonly in the elderly, with almost 50% diagnosed in patients
aged X70 years (Havlik et al, 1994).
Although third-generation doublets, platinum-based regimens,
represent the gold standard in the treatment of advanced NSCLC
patients who have good performance status (PS), most elderly
advanced patients may be more susceptible to the toxic side effects
of platinum-containing combinations due to higher rates of
comorbid illness and the age-related impairment of organ function
so that single-agent chemotherapy, such as gemcitabine, is
considered a valid therapeutic choice (Gridelli et al, 2003; Pfister
et al, 2004). Moreover, the large randomised phase III MILES-trial
concluded that the non-platinum containing regimen vinorelbine
plus gemcitabine did not provide a survival benefit over single-
agent vinorelbine or gemcitabine, and that the two-drugs
combination was more toxic than single-agent therapy (Gridelli
et al, 2003).
Among the last generation drugs tested in NSCLC, docetaxel
seems very promising. This drug has shown single-agent efficacy
as a second-line treatment: in patients pre-treated with platinum-
based chemotherapy as a first-line therapy, single-agent docetaxel
proved to have a survival advantage over best supportive care
alone (Shepherd et al, 2000), and in comparison to vinorelbine or
ifosfamide alone (Fossella et al, 2000).
This drug also showed activity as a single agent in untreated
elderly advanced NSCLC patients enrolled in the West Japan
Thoracic Oncology Group Phase III Trial (WJTOG 9904),
comparing docetaxel 60mgm
 2 to vinorelbine 25mgm
 2 on days
1 and 8 every 3 weeks. Indeed a statistically significant advantage
in terms of progression-free survival (5.5 vs 3.1 months), response
rate (22.7 vs 9.9%), and improvement of disease-related symptoms
was observed in favour of docetaxel; docetaxel had a non-
significantly prolonged median overall survival (14.4 vs 9.9
months) (Kudoh et al, 2006). In the first line setting, docetaxel
demonstrated both an interesting activity and efficacy whether
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scombined with a platinum compound (Fossella et al, 2003) or with
gemcitabine. In particular, among non-platinum-based chemo-
therapy regimens, the combination docetaxel–gemcitabine is
considered one of the most promising. In fact, a randomised
phase II trial and two randomised phase III trials compared this
association with last generation platinum-containing doublets,
docetaxel–cisplatin (Georgoulias et al, 2001) and cisplatin–
vinorelbine (Georgoulias et al, 2005; Pujol et al, 2005) yielding
similar activity and efficacy. Therefore, the combination
docetaxel–gemcitabine could be considered a regimen to test in
elderly subjects, as tolerability, especially haematological toxicity,
can be problematic (Georgoulias et al, 2005; Pujol et al, 2005;
Manegold et al, 2006).
A possible approach to reduce the toxicity of combination
regimens consists of administering the same drugs in a sequential
manner. This strategy may allow the administration of full dose
single agents sequentially without compromising efficacy, while
reducing potential toxicity expected with concurrent administra-
tion. Preclinical models (Norton and Simon, 1977; Day, 1986) as
well as recent clinical trial in NSCLC suggest a benefit for the
sequential administration of chemotherapy agents. A randomised
phase III trial on advanced NSCLC (Manegold et al, 2006), having
clinically relevant haematological toxicity (defined as thrombocyto-
penia with platelets transfusions, anaemia with RBC-transfusions
or febrile neutropenia) as a primary end point, compared a
concomitant administration of gemcitabine 1000mgm
 2 on days 1
and 8 and docetaxel 75mgm
 2 on day 1 every three weeks for 6
courses vs their sequential administration (3 courses of gemcita-
bine followed by 3 courses of docetaxel at the same dosages).
Clinically relevant haematological toxicity occurred less frequently
in the sequential arm and the quality of life also improved with this
approach.
Three randomised phase III trials (Gridelli et al, 2004; Schuette
et al, 2005; Camps et al, 2006) have compared, in second line
advanced NSCLC, docetaxel at the dose of 75mgm
 2 every 3
weeks, considered the standard of care, against a weekly schedule,
indicating a similar efficacy but a significantly less severe toxicity
in terms of leukopenia, neutropenia and febrile neutropenia with
weekly docetaxel.
We carried out a multicenter phase II study to evaluate the
activity, efficacy and tolerability, of a sequential regimen consisting
of three courses of gemcitabine followed by three courses of
docetaxel provided there was no evidence of disease progression.
The schedule chosen for docetaxel was 37.5mgm
 2 on days 1 and
8 every 3 weeks according to our previous study carried out in
elderly patients in a second-line setting (Tibaldi et al, 2006; Gridelli
et al, 2007b).
PATIENTS AND METHODS
Patient selection criteria
Chemotherapy-naive patients with histologically or cytologically
confirmed NSCLC, aged X70 years, measurable disease, and
clinical stage IIIB (cytologically positive pleural effusion or
metastatic supraclavicular lymph nodes) or stage IV disease were
eligible if they also met the following criteria: Eastern Cooperative
Oncology Group PS p2, life expectancy 43 months, adequate
bone marrow reserve (leukocyte count X4.0 10
9l
 1, platelet
count X100 10
9l
 1), adequate hepatic function (bilirubin level
p1.5mgdl
 1) and renal function (creatinine level p1.5mgdl
 1).
Prior radiotherapy was allowed provided that the irradiated area
was not the only source of measurable disease and that radiation
therapy had been completed 7 days before chemotherapy was
initiated.
Patients were excluded for the presence of active infections,
concomitant malignancy, or a second primary malignancy, recent
myocardial infarction, unstable angina, congestive heart failure,
dementia, symptomatic brain metastases. A written informed
consent was obtained from each patient before enrolment. The
protocol was approved by each local ethics committee of every
institution participating to the study and the trial was conducted
according to the Helsinki declaration of the World Medical
Association.
Treatment
The chemotherapy regimen consisted of gemcitabine (Gemzar
s,
Eli Lilly and Company, Indianapolis, Indiana, USA) 1200mgm
 2
in 250ml of normal saline administered intravenously over 30min
on days 1 and 8 every 3 weeks for 3 courses followed by, docetaxel
(Taxotere
s, Aventis Pharma, Antony Cedex, France) 37.5mgm
 2
in 500ml of normal saline administered intravenously over 60min
on days 1 and 8 every 3 weeks for 3 courses, provided there was no
evidence of disease progression; premedication consisted of 20mg
dexamethasone i.v. and 5-hydroxytryptamine-3 receptor antago-
nists as antiemetic prophylaxis. Patients whose white blood cell
count, neutrophil count and platelet count were greater than
3.5 10
9, 1.5 10
9 and 100 10
9l
 1, respectively, received chemo-
therapy on day 1. If these conditions were not met, administration
of chemotherapy was delayed 1 week or until recovery.
A dose delay for more than 3 weeks resulted in withdrawal from
the study. The dose of chemotherapy (gemcitabine and docetaxel)
was modified on day 8 according to haematological and non-
haematological toxicities as follows: if neutrophil count was
41.5 10
9l
 1 and platelet count was 4100 10
9l
 1,c h e m o t h e r a p y
was administered at full dose; for neutrophil count 1.0–
1.49 10
9l
 1 or platelet count 75–99 10
9l
 1, the dose was
reduced by 25%; for neutrophil count 0.5–0.99 10
9l
 1 or platelet
count 50–74 10
9l
 1 the dose was reduced by 50%; for neutrophil
count o0.5 10
9l
 1 or platelet count o50 10
9l
 1, chemother-
apy was omitted. If grade 2 non-haematological toxicity (except for
alopecia) was observed, chemotherapy was omitted until resolu-
tion and then readministered at the next cycle at doses reduced by
25–50%. In case of grade 2 neurological toxicity or grade 3–4 non-
haematological toxicity the patient was withdrawn from the study.
The routine use of granulocyte colony-stimulating factor was
not allowed.
Evaluation criteria
Pretreatment evaluation included medical history, physical
examination, assessment of PS, complete blood cell count with
differential, routine chemistry, chest radiograph, computed
tomography (CT) scan of the chest and abdomen. A comorbidities
assessment using the Charlson comorbidity index was carried out
(Charlson et al, 1987). In particular, the presence or absence of
the following disease states was recorded: myocardial infarction,
peripheral vascular disease, cerebrovascular disease, chronic
pulmonary disease, connective tissue disease, ulcer disease, mild
liver disease, diabetes, hemiplegia; each disease state had a
corresponding numeric value (Charlson et al, 1987), and the value
for all present disease states were summed for each patient. The
other pathologic conditions (congestive heart failure, dementia,
moderate or severe kidney disease, diabetes with organ damage,
any other cancer, moderate or severe liver disease, AIDS), used to
calculate the Charlson score, were not taken into account because
they were precluded by the exclusion criteria for the study.
During treatment, a complete blood cell count was performed
before each chemotherapy administration. Eastern Cooperative
Oncology Group PS was evaluated at each cycle. Evaluation of
tumour response was carried out with CT scan every three cycles.
Responses were assessed using standard RECIST criteria (Therasse
et al, 2000). The best overall response for each patient was
reported; all results were reviewed by an independent radiologist
Sequential chemotherapy in elderly advanced NSCLC
C Tibaldi et al
559
British Journal of Cancer (2008) 98(3), 558–563 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sand had to be confirmed 28 days or more after initial
documentation of the response. Patients with disease progression
after 3 courses of gemcitabine were considered as such in the final
analysis. The overall response rate was calculated according to the
intention-to-treat analysis.
Haematological toxicity and non-haematological toxicities were
recorded at days 1 and 8 of every course of treatment. The worst
toxicity grade for each patient in all cycles was reported. Toxicities
were assessed using National Cancer Institute common toxicity
criteria version 2.0 (NCI-CTC) (National Cancer Institute, 1999).
Quality of life was assessed using the European Organisation for
Research and Treatment (EORTC) QLQ-C30 questionnaire
(version 3.0) and the lung cancer-specific module (QLQ-LC13).
Patients were asked to complete the questionnaires at baseline and
at the end of every cycle.
Statistical analysis
The main objective of the study was to test whether the sequential
combination of gemcitabine and docetaxel would improve
response rate. Secondary end points were to evaluate toxicity,
time to progression and survival. Simon’s two-stage minimax
design was applied to calculate the sample size. Assuming p0 (low
response rate) 20% and p1 (target response rate of interest for
further investigation) 35% and with an a error of 0.05 and a b error
of 0.20 a total of 31 evaluable patients had to be accrued during
stage 1. If at least six objective responses were observed, 22
additional patients were to be enrolled into the study during stage
2. The regimen would be considered for further investigation if
X15 objective responses out of 53 evaluable patients were
observed.
Time to progression (TTP) was calculated from the date of
registration to the date of clinical and/or radiological evidence of
progression or death, whichever occurred first. Survival was
calculated from registration to death or last follow-up. Survival
and TTP were estimated using the Kaplan–Meier method.
Since most patients had more than one comorbid medical
condition, the comorbidities count was dichotomised as 0–1 or
41 whereas Charlson score was dichotomised as 0 or X1, as
reported previously (Hesketh et al, 2006), for survival compar-
isons. Cox regression analyses were used to examine any possible
relationships between overall survival and comorbidities count or
Charlson score.
Data were analysed using SPSS/PCþ11.5statistical software
(SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
From March 2005 to October 2006, 56 patients entered the study
(Table 1). Forty-six patients (82%) were males, 10 (18%) were
females; median age was 76 years (range 70–84). Seven patients
(12.5%) had a PS¼0, 38 patients had a PS¼1 (67.8%), 11 patients
had a PS¼2 (19.6%). Squamous carcinoma was the most frequent
histology (20 patients); 17 patients had adenocarcinoma, one
patient had bronchioloalveolar carcinoma, four patients presented
large cell carcinoma and 14 patients had undifferentiated NSCLC.
All patients had stage IV disease. Table 2 shows the distribution of
comorbid conditions.
Dose administration
Fifty-six patients received a total of 243 cycles, 159 cycles of
gemcitabine and 84 cycles of docetaxel; the median number of total
courses (gemcitabine plus docetaxel) was 5 (range, 1–6). Thirty-
two patients received docetaxel and the median number of
docetaxel courses was 3 (range 1–3). The delivered dose-intensity
for gemcitabine and docetaxel was 690.4 and 20.3mgm
 2 per
week, respectively, whereas the relative dose intensity was 86.2 and
81.2%, respectively. Twelve delays (7.5% of the courses) were
reported during gemcitabine treatment. Toxicity was the reason
Table 1 Clinical characteristics
No of patients (%)
No of Patients: 56
Age, years (range) 76 (70–84)
Sex
Male 46 (82)
Female 10 (18)
Smoking history
Smokers 48 (85.7)
Never smokers 8 (14.3)
ECOG PS
0 7 (12.5)
1 38 (67.8)
2 11 (19.6)
Histology
Adenocarcinoma 17 (30.4)
Squamous 20 (35.7)
Large cell 4 (7.1)
Bronchioloalveolar 1 (1.8)
Unspecified NSCLC 14 (25.0)
Metastatic sites
Bone 14 (25.0)
Brain 6 (10.7)
Liver 4 (7.1)
Adrenal gland 7 (12.5)
Lymphonodes 29 (51.8)
Pleura 11 (19.6)
Lung 14 (25.0)
Number of comorbidities
None 3 (5.3)
1 21 (37.6)
2 15 (26.7)
3 12 (21.4)
4 5 (9)
Charlson score
0 18 (32.1)
1 28 (50.0)
2 10 (17.8)
Table 2 Comorbid conditions
No of patients (%)
Myocardial infarction 5 (8.9)
Ischaemic heart disease 6 (10.7)
Valvular heart disease 1 (1.8)
Atrial fibrillation 5 (8.9)
Peripheral vascular disease 3 (5.4)
Cerebrovascular disease 6 (10.7)
Hypertension 26 (46.4)
Chronic pulmonary disease 11 (19.6)
Mild liver disease 3 (5.4)
Peptic ulcer 7 (12.5)
Diabetes 12 (21.4)
Connective tissue disease 1 (1.8)
Osteoporosis 5 (8.9)
Mild depression 2 (3.6)
Mild kidney disease 4 (7.1)
Genitourinary diseases 10 (17.9)
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sfor the delays in only three cases (1 episode of grade 2 neutropenia,
1 episode of grade 2 skin toxicity and 1 episode of AST and ALT
elevation); the reasons for the other nine delays were fever in three
cases and scheduling conflict in six cases. Seventeen delays (20.2%
of the courses) were reported during docetaxel treatment. The
reasons for the delays were one episode of grade 3 mucositis, two
episodes of grade 3 diarrhoea, one episode of grade 3 neutropenia,
two episodes of grade 2 skin toxicity, one episode of creatinine
increase and one episode of bilirubin increase; in nine cases the
reasons were not related to toxicity (fever in five cases and
scheduling conflict in four cases). Six patients discontinued
treatment due to docetaxel toxicity: one patient experienced grade
4 mucositis, one patient had grade 3 mucositis, one patient
experienced grade 4 skin toxicity, two patients reported grade 3
asthenia and one patient had an allergic reaction; three patients
didn’t discontinue treatment although they reported grade 3
asthenia. The gemcitabine dose was reduced by 25% in six
administrations whereas the docetaxel dose was reduced by 25% in
16 administrations, and by 50% in four administrations.
Response and survival
Fifty-three out of 56 patients were evaluable for response. Three
patients could not be evaluated for the following reasons: one
patient refused to continue chemotherapy after the first cycle, one
patient died before the first evaluation probably due to rapid
tumour progression, one patient was lost to the follow-up; these
three patients were considered as progression disease in the final
analysis.
According to the intention-to-treat analysis, the overall response
rate was 16.0% (9 out of 56 patients) (95% CI 7.6–28.3%); twenty-
three patients (41.0%) had stable disease and twenty-four patients
(43%) had progressive disease. Five patients who had a stable
disease after three courses of gemcitabine obtained a conversion to
partial response by docetaxel.
Median time to progression was 4.8 months (95% CI 3.6–6.0
months) and median duration of survival was 8.0 months (95% CI
5.6–10.5 months). The 1-year survival rate was 34% (Figure 1). At
an exploratory planned analysis, the subgroup of patients with PS
0–1 had a median time to progression of 4.8 months (95% CI 2.6–
7.0 months), a median duration of survival of 8.7 months (95% CI
7.4–9.9 months) and 1-year survival rate of 40%; patients with PS
2 reported a median time to progression and a median overall
survival of 4.0 months (95% CI 0.6–7.3 months) and 5.4 months
(1.3–9.4 months), respectively, with a 1-year survival rate of 15%.
Patients with a Charlson score of 0 (18 patients) or X1 (38
patients) had a median survival of 9.7 months and 7.9 months,
respectively (P¼0.82).
Since several comorbidities were not taken into account by
Charlson score we analysed the median survival according to the
number of comorbidities: the median survival was 8.6 months for
patients with 0–1 comorbidities and 5.4 months for patients with
41 comorbidities (P¼0.64).
Although planned, quality of life assessment isn’t reported
because of the lacking of sufficient data due to the high rate of
missing questionnaires.
Toxicity
All 56 patients were evaluable for toxicity. Observed toxicities were
mild and the compliance to treatment was good. No grade 4
haematological toxicity was observed and grade 3 neutropenia and
thrombocytopenia were reported in 5.4 and 3.6% of the patients,
respectively. No patients developed febrile neutropenia or
haemorrhages. Non-haematological toxicity consisted mainly in
grade 3/4 mucositis and grade 3 diarrhoea both occurring in two
(3.6%) patients, grade 3 asthenia observed in five (9%) patients.
One patient reported a grade 4 skin toxicity and two patients
reported a grade 3 nail toxicity. No treatment-related deaths
occurred. Haematological and non-haematological toxicities are
summarised in Table 3.
DISCUSSION
The present trial, targeting elderly (age 70 years and older)
advanced-stage NSCLC patients, was designed to test the hypo-
thesis that planned sequential administration of gemcitabine
followed by docetaxel may improve response rate with good
tolerability. We hypothesised that the introduction of docetaxel in
our first line sequential regimen could enhance the response rate
with respect to our previous trial carried out in 110 elderly
advanced NSCLC patients treated with gemcitabine alone (Tibaldi
et al, 2005). In the present trial, the overall response rate according
to an intention to treat analysis was 16.0% that was similar to our
previous trial (13.9%). Nevertheless, it is remarkable that five out
of nine responses that we observed were obtained from a
conversion of stable disease to partial response by docetaxel.
We observed a median time to progression (TTP) of 4.8 months,
a median overall survival (OS) of 8.0 months, and 1-year survival
rate of 34%, that can be considered encouraging. In our previous
trial, in fact, we reported a median TTP of 3.2 months, a median
OS of 5.4 months and 1-year survival rate of 27% (Tibaldi et al,
2005). In addition, the percentage of PS 2 patients enrolled in both
trials was similar at 20%.
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Figure 1 Kaplan–Meier plot of overall survival (OS) and time to
progression (TTP).
Table 3 Haematological and non-haematological toxicity per patient
NCI-CTC grade % (56 patients)
12 3 4
Neutropenia 12.5 10.7 5.4 0
Thrombocytopenia 8.9 1.8 3.6 0
Anaemia 46.4 18 0 0
Nausea/vomiting 23.2 3.6 0 0
Diarrhoea 14.3 3.6 3.6 0
Mucositis 16.1 3.6 1.8 1.8
Asthenia 20 32 9 0
Nail toxicity 15 3.6 – –
Skin toxicity 5.4 3.6 0 1.8
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sThe introduction of docetaxel in first-line treatment of advanced
NSCLC resulted advantageous in progression-free survival in a
recent randomised phase III trial that compared immediate
docetaxel with docetaxel upon evidence of progression in non-
progressing patients after four cycles of induction therapy with
gemcitabine plus carboplatin. The progression-free survival in the
immediate docetaxel arm (6.5 months) was significantly greater
(P¼0.0001) than in the delayed docetaxel arm (2.8 months)
(Fidias et al, 2007).
Haematological and non-haematological toxicities, in our study,
were mild and acceptable. The compliance to treatment was in
general good. In particular, the present trial confirms our previous
observation (Tibaldi et al, 2006) that a modified schedule of
docetaxel (37.5mgm
 2 on days 1 and 8 every 3 weeks) is feasible
and well tolerated in elderly advanced NSCLC patients. Our
tolerability data confirm the previous observations that weekly
docetaxel is advantageous in terms of haematological toxicity with
respect to 3-weekly schedule (Gridelli et al, 2004; Schuette et al,
2005; Camps et al, 2006).
Recently, the results of the SWOG (S0027) phase II trial using a
sequential regimen of vinorelbine 25mgm
 2 on days 1 and 8 every
3 weeks for three cycles followed by three courses of docetaxel
35mgm
 2 on days 1, 8, 15 every 4 weeks in patients 70 years of age
and older and in patients with PS two of any age were published
(Hesketh et al, 2006). Patients aged X70 years with a PS of 0–1
had a median TTP and a median OS, of 4.7 and 9.1 months
respectively, comparable to our results. However, some toxicities
were more common such as grade 3/4 neutropenia and grade 3/4
fatigue, seen in 32 and 22% of patients, respectively. Another
recent randomised phase II trial evaluated chemotherapy with
pemetrexed alone vs a sequential pemetrexed/gemcitabine regimen
in patients who were elderly (X70 years) or younger than 70 years
and ineligible for platinum-based chemotherapy. The median TTP
and OS reported were lower than expected and equal, in both arms,
to 4.1 and 5.4 months, respectively (Gridelli et al, 2007a). A
possible explanation for these results might be the high proportion
of PS 2 patients (35.6%), who have poorer prognosis, enrolled into
this study. However, although some trials grouped elderly patients
with PS 2 patients of any age, these cohorts of patients have
probably different characteristics and prognosis and should be
included in different and specific dedicated clinical trials in the
future.
Two multicenter phase II trials evaluated a weekly combination
regimen of docetaxel and gemcitabine in advanced NSCLC; the
first trial (Neubauer et al, 2005) reported a response rate of 20%,
a median TTP and OS of 5.1 and 6.9 months, respectively, that
favourably compare with our results; the second trial, that used a
patient selection criteria based on age, PS and Charlson score,
reported a higher response rate of 34%, but a similar median TTP
and OS of 5 and 7 months, respectively (LeCaer et al, 2007).
However, the frequency of grade III–IV fatigue was high and
reported in 30% of patients.
In our study, we did not observe significant differences in
overall survival according to Charlson score (0 or 41); although,
the Charlson score did not correlate with PS (Dujon et al, 2006),
it seems to be insufficient to screen elderly advanced NSCLC
patients (Maione et al, 2005). The use of a comprehensive geriatric
assessment, according to the recommendations of the SIOG
(Extermann et al, 2005), appears crucial to improve the selection
and stratification of elderly patients and thereby to allow valid
comparisons among different studies.
In this setting, quality of life evaluation has prognostic value for
survival (Maione et al, 2005); nevertheless, in our study we did not
report this analysis because of a lack of sufficient questionnaires
and quality of life assessment should be recommended in future
trials.
At present, the role of platinum-based combinations in elderly
advanced NSCLC is not clear; retrospective subset analyses of a
number of phase III trials suggested that combination platinum-
based therapy is superior to single agents in both younger and
older patients (Langer et al, 2002; Lilenbaum et al, 2005); however,
prospective randomised trials are lacking to confirm this
hypothesis and the results of the MILES-2 study, comparing
gemcitabine vs cisplatin/vinorelbine and vs cisplatin/gemcitabine,
are eagerly awaited.
In conclusion, our results suggest that the sequential use of
gemcitabine and docetaxel is another viable, option for elderly
advanced NSCLC patients. The use of standardised specific
geriatric evaluations appears to be crucial for future trials in this
setting.
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